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Summary: Thrombocytopenia presenting during early childhood is
most commonly diagnosed as immune/idiopathic thrombocytopenic
purpura (ITP), where the antibody-mediated destruction of throm-
bocytes is often transient. If treatment is indicated, the majority of
patients respond to immune-modulation by intravenous immuno-
globulin G infusion or systemic corticosteroids. Differential diagnoses
to childhood ITP includes thrombocytopenia due to infections, drugs,
rheumatologic conditions, immune dysregulation, and inherited bone
marrow failures, for example, congenital amegakaryocytic thrombo-
cytopenia. Isolated thrombocytopenia in an otherwise healthy appear-
ing child that recurs after therapy and/or persists suggest a differential
diagnosis rather than ITP. We present a case of symptomatic
thrombocytopenia in a 2-year-old girl associated with adenosine
deaminase deﬁciency.
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CASE REPORT
A 2-year-old girl presented to the emergency room with a
3-day history of widespread petechiae (ie, face, abdomen, extremities) and
cutaneous hematomas (mainly lower extremities) that developed without
signiﬁcant trauma. A few petechial bleedings were seen in the oral
mucosa, but no other signs of bleeding could be found. Beside the
cutaneous bleedings, the recent medical history was unremarkable (eg, no
recent infections, no other complaints, and no recent new medications).
Vital signs were stable and physical examination was unremarkable, apart
from the presence of a slightly enlarged spleen. Laboratories on pre-
sentation were signiﬁcant for a white blood cell (4.4×109/L), neutrophils
(1.2×109/L), lymphocytes (2.5×109/L), thrombocytes (<5×109/L), hemo-
globin (Hb) (113 g/L), erythrocytes (4.7×1012/L), and reticulocytes
(97×109/L). A peripheral blood smear displayed lymphocytopenia and
neutropenia as the only deviations.
The patient was the ﬁrst child of nonconsanguineous parents of
northern European decent. Family history was unremarkable with no
reports of hematologic/immunologic conditions nor early-onset stroke.
The medical history included an eventful pregnancy with delivery at term
by vacuum extraction due to fetal distress and need for ventilation brieﬂy.
Fetal anemia (Hb, 80 g/L) was noted at the neonatal ward. Investigations
could not identify any cause (ie, no signs of fetal-maternal transfusion,
immunization, etc.). The baby was prescribed iron substitution that
was discontinued after 4 months upon normalization of the Hb level
(113 g/L). Neonatal cranial sonography identiﬁed a small parietal area
with increased echogenicity where a magnetic resonance imaging follow-
up could not conﬁrm any pathology. After discharge from the neonatal
ward, the girl had normal growth and psychomotor development and
only a few medical consultations, mainly due to common viral infections.
An abdominal ultrasound, to investigate the splenomegaly,
showed a slightly enlarged spleen with multiple small irregular hypo-
echogenic areas. Primary differential diagnoses included immune/idio-
pathic thrombocytopenic purpura (ITP) or hematologic malignancy and
further workup included a bone marrow examination. A thrombocyte
transfusion was given before the invasive diagnostic procedure and
resulted in a transient discrete increase in platelet count (7×109/L). The
results of the bone marrow examination were unremarkable with nor-
mal megakaryocytopoiesis. Intravenous immunoglobulin G (IVIg) was
infused leading to rapidly increasing thrombocyte counts on the foll-
owing day (58×109/L) that was sustained 2 days later (73×109/L).
Hence, the patient was discharged with a diagnosis of suspected ITP and
further outpatient follow-up was scheduled, including additional diag-
nostic investigations on the enlarged spleen. During the following
2 months the patients symptomatic thrombocytopenia reoccurred on
multiple occasions and repeated single dose infusions of IVIg 1 g/kg were
only able to elevate the thrombocyte count >5×109/L for 7 to 10 days.
The patient also had a constantly elevated erythrocyte sedimentation
rate (ESR, 55mm/h) that was not affected by the IVIg therapy.
Treatment with oral corticosteroids was initiated and the peripheral
thrombocyte count (208×109/L) and ESR were normalized after
5 months of 10mg prednisone daily. After 6 months, a further tapering
of prednisone to a dose of 5mg per day led to a rapid decline of
peripheral thrombocytes and the previous dose had to be reinstated.
In light of the intriguing clinical picture, that is, not fully con-
sistent with ITP, extensive immunologic workup and whole genome
sequencing were performed. Immunologic workup was remarkable for
a decreased amount of peripheral B cells (0.28×109/L), a slightly
increased proportion of double negative (CD4−, CD8−) T cells (3.7%)
and serum interleukin-10 was also elevated at 25.1 ng/L. The remain-
der of the workup was unremarkable including normal levels of serum
immunoglobulins (assessed >6mo after the last dose of IVIg) and
normal activation of T cells and B cells to stimulation with mitogens,
as assessed by our clinically operational FASCIA analysis.1
Whole genome sequencing showed the presence of 2 missense
mutations in CECR1 (c.506G>A and c.932T>G), leading to 2 amino
acid substitutions in adenosine deaminase (ADA) 2 (p.Arg169Gln and p.
Leu311Arg). The c.506G>A variant has been previously associated with
ADA2 deﬁciency as a compound heterozygous variant in the context of
early-onset stroke and vasculopathy, as well as with a variable clinical
phenotype in a case series of individuals who were all homozygous for
the variant.2,3 The c.932T>G variant is however novel, but several
variant evaluation metrics predicted it to be deleterious (SIFT, Mutation
Taster, and FATHMM) and the variant had a deleterious annotation of
genetic variants using neural networks score of 0.9967.4 Both of the
variants were conﬁrmed by Sanger-sequencing and the patient’s parents
were identiﬁed to be heterozygous carriers (Fig. 1). To evaluate the effect
of the CECR1 variants on protein function, the activity of ADA2 from
the patient was tested. Samples from the patient showed severely
impaired activity of ADA2 as compared with healthy controls (Fig. 2),
thus conﬁrming the predicted deleterious effect of the 2 compound
heterozygous missense variants.
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In light of the previously published association between CECR1
variants, impaired ADA2 activity, and the development of early-onset
stroke and vasculopathy, in combination with the patients thrombocy-
topenia, stem cell transplantation (SCT) was considered, as it has pre-
viously been shown to be effective.3,5 The patients general good health,
normal development, and absence of overt signs of vasculopathy,
however, prompted us to initiate therapy with the tumour necrosis
factor inhibitor adalimumab, as it has been associated in case reports
with improved outcomes in patients with deﬁciency of ADA2.3,6,7 The
patient has now been treated for 6 months with adalimumab mono-
therapy and appears clinically well with slightly decreased thrombocyte
counts (122×109/L) and mild lymphocytopenia (2.0×109/L). The ESR is
FIGURE 1. Sanger-sequencing of the patient and her parents. Arrows indicate the heterozygous variants.
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normalized and the splenomegaly has resolved, whereas interleukin-10
remains elevated at a lower level (13.6 ng/mL). Oral corticosteroid
therapy has been stopped and clinical evaluation as well as magnetic
resonance imaging of the brain has shown no clinically signiﬁcant
evidence of progressive vasculopathy.
DISCUSSION
Although deﬁciency of ADA1 is associated with early
developing severe combined immunodeﬁciency, deﬁciency
of ADA2 (DADA2) has been linked to a highly variable
clinical syndrome in previously published cases.2,3,6,8 It is
tempting to speculate that this variability is caused by diff-
erences in the described missense variants, leading to diff-
erential effects on ADA2 functional activity. A recent study
by Van Montfrans et al3 describing the variable clinical
picture in a case series of children who were all homozygous
for the c.506G>A variant, however, argues for a more
complex regulation of the ADA2 activity.
ADA2 expression seems to be particularly high in the
spleen and while the presence of increased levels of adeno-
sine have been linked to both proinﬂammatory and immu-
noregulatory effects on immunologic cells, several aspects of
our case argues for a regulatory role of functioning ADA2
in the current clinical situation.7,9–11 First, the slight sple-
nomegaly coupled with the normal appearing bone marrow
and the rapid increase in peripheral thrombocytes after
initiated therapy argues for an increased consumption of
thrombocytes as the main cause of thrombocytopenia.
Second, the absence of overt signs of disseminated intra-
vascular coagulation as well as the absence of large volume
blood loss argues for phagocytosis-driven consumption as
the main mechanism of consumption. Third, the rapid
response to therapies with immunosuppressive properties
(IVIg, corticosteroids, and tumour necrosis factor-α inhibition)
as well as a normalization of a previously elevated ESR
also argues for a primarily regulatory function of ADA2 in
the present context. Whether functional ADA2 exerts its
regulatory effects through conversion of adenosine to inosine,
through binding to cell surface receptors on lymphocytes or
through some yet unknown mechanism, however remains to
be elucidated.
In light of the current clinical literature on DADA2,
decisions on treatment strategy remain challenging. The
correlation of the degree of diminished ADA2 in vitro
activity with the level of increased risk of early-onset stroke,
coupled to the probable devastating clinical consequences of
such an event makes SCT a valid treatment option.5–7 SCT
however, is naturally also associated with several short and
long-term adverse effects, which makes it a challenging
treatment option for patients, especially if other less haz-
ardous treatments are available. We decided to treat the
current patient with, the for DADA2 investigational drug,
adalimumab, mainly based on earlier reports of clinical
success coupled to the absence of clinical or radiologic signs
of overt vasculopathy.3,6,7
In conclusion, we present a case of symptomatic
thrombocytopenia presenting in early childhood that was
associated with DADA2 and we suggest that DADA2
should be incorporated into the differential diagnosis of
thrombocytopenic children. Our case also noticeably illus-
trates the importance of the publication of treatment out-
comes in rare diseases, of genetically well-characterized
patients; to assist in the further development of personalized
sequencing-based clinical medicine.
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FIGURE 2. The ADA activity assay (Diazyme, Poway, CA) was
slightly modified by adding erythro-9-(2-hydroxy-3-nonyl)ade-
nine (Sigma-Aldrich, Zwijndrecht, the Netherlands) for ADA1
inhibition to allow discrimination between ADA1 and ADA2. Box
plots represent mean± SD of 21 HCs. Patient samples were
measured in duplicates with identical measurements. ADA indicates
adenosine deaminase; HC, healthy control.
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